IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
Author(s)
Moderator: Mireia Jofre-Bonet, PhD, Office of Health Economics, London, UK
Panelists: Andrew Briggs, DPhil, Health Economics & Health Technology Assessment, Institute of Health and Wellbeing, University of Glasgow, Glasgow, Scotland, UK; Adrian Towse, MA, MPhil, Office of Health Economics, London, UK; Inneke Van de Vijver, MSc, National Institute for Health and Disability Insurance, Brussels, Belgium
Presentation Documents
ISSUE: Feasibility and Desirability of Indication Based Pricing (IBP)
OVERVIEW: With this panel, we want to ignite a sound debate on whether IBP can be implemented as an alternative pricing mechanism. Also, we want to discuss whether IBP could be beneficial for society and, if so, under which conditions it may be.
We bring together three views: that of someone who believes it may work, that of someone who is not convinced and that of someone knowledgeable of the payer's perspective. This discussion promises to be well attended and of high interest for all stakeholders: payers, industry, patients and policy makers.Conference/Value in Health Info
2019-11, ISPOR Europe 2019, Copenhagen, Denmark
Code
IP6